Witryna25 mar 2024 · Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial - The Lancet Respiratory Medicine Articles Volume 7, ISSUE 5, P387-401, May 2024
最新最全面肺癌肝转移治疗方案 如何最大化药物治疗优势?如何筛 …
Witrynaa 32 patients in the atezo + CnP arm and 12 patients in the CnP arm had EGFR or ALK genomic alterations and were not included in the ITT-WT population. b PD-L1-high (TC3 or IC3): patients with PD-L1 expression in ≥50% of TC or ≥10% of IC. c PD-L1-low (TC1/2 or IC1/2): patients with PD-L1 expression in ≥1% and <50% of TC or ≥1% and … WitrynaConclusions: At the final IMpower150 OS analysis, ACP had numerical, but not statistically significant, OS improvement versus BCP. Updated data with an additional … tssa piping registration flow chart
IMpower130: efficacy and safety from a randomised phase 3 study …
Witryna11 kwi 2024 · IMpower150研究对比了阿替利珠单抗+化疗(卡铂+紫杉醇)+贝伐珠单抗联合治疗vs化疗+贝伐珠单抗。一线治疗的话,阿替利珠联合组显著延长总体患者的OS 19.2个月 vs 14.7个月;对肝转移亚组,阿替利珠联合组也可将OS延长4.1个月,达到13.2 … WitrynaAtezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline … Witryna16 sty 2024 · 亚组分析提示, IMpower150 研究是目前唯一免疫联合治疗在 EGFR 敏感突变亚组 NSCLC 患者中 OS 获益的随机前瞻性Ⅲ期临床试验 。 对于 EGFR TKI 治疗失败的后线治疗,在贝伐珠单抗 + 化疗的标准疗法基础上联合阿替利珠单抗,将成为一种新的 … phison ps2307 mptool